---

         T R O U B L E D   C O M P A N Y   R E P O R T E R

              Saturday, December 2, 2023, Vol. 27, No. 335

                            Headlines

AMYRIS INC: Narrows Net Loss in October to $26.82 Million
NOVAN INC: Posts $1.09 Million Net Loss for October

                            *********

AMYRIS INC: Narrows Net Loss in October to $26.82 Million
----------------------------------------------------------
Amyris Inc. filed with the U.S. Securities and Exchange Commission
its monthly operating report for October 2023.

The Debtor's statement of operations reflected a net loss of $26.82
million for October, a big dip from September's $84 million net
loss.

As of October 31, 2023, the Debtor listed $819.59 million in total
assets, $1.27 billion in total liabilities, and -$452.28 million in
total shareholders' equity.

The Debtor started the month with $29.55 million cash. It listed
total receipts of $38.35 million and total disbursements of $38.96
million. At month end, the Debtor had $28.92 million cash.

A copy of the monthly operating report is available at the SEC at:

                  https://tinyurl.com/2a5ypv54

                       About Amyris Inc.

Amyris (Nasdaq: AMRS) -- http://www.amyris.com/-- is a leading
synthetic biotechnology company, transitioning the Clean Health &
Beauty and Flavors & Fragrances markets to sustainable ingredients
through fermentation and the company's proprietary
Lab-to-Market(TM) technology platform.  This Amyris platform
leverages state-of-the-art machine learning, robotics and
artificial intelligence, enabling the company to rapidly bring new
innovation to market at commercial scale.  Amyris ingredients are
included in over 20,000 products from the world's top brands,
reaching more than 300 million consumers.  Amyris also owns and
operates a family of consumer brands that is constantly evolving to
meet the growing demand for sustainable, effective and accessible
products.

Amyris, Inc, et al., sought protection under Chapter 11 of the
Bankruptcy Code (Bankr. D. Del. Lead Case No. 23-11131) on Aug. 9,
2023.  The petitions were signed by Han Kieftenbeld as interim
chief executive officer & chief financial officer.

In the petition, Amyris disclosed $679,679,000 in assets and
$1,327,747,000 in liabilities.

Pachulski Stang Ziehl & Jones LLp serves as the Debtors' bankruptcy
counsel.  Fenwick & West, LLP is the Debtorps corporate counsel.
The Debtors tapped PricewaterhouseCoopers LLP as their financial
advisor, while Intrepid Investment Bankers LLC serves as the
Debtors' investment banker.  Stretto, Inc., is the Debtors' claims,
noticing, solicitation agent and administrative adviser.


NOVAN INC: Posts $1.09 Million Net Loss for October
---------------------------------------------------
Novan Inc., nka NVN Liquidation, Inc., along with its wholly owned
subsidiary, EPI Health, LLC, filed with the U.S. Securities and
Exchange Commission their monthly operating reports for October
2023.

NVN's statement of operations reflected a net loss of $1.09 million
in October.

As of October 31, 2023, NVN listed $6.84 million in total assets,
$5.32 million in total liabilities, and $1.52 million in total
shareholders' equity.

NVN started the month with $6.4 million cash. It listed total cash
receipts of $41,515 and total disbursements of $2.6 million. At
month end, NVN had $3.84 million cash.

In addition, EPI Health's statement of operations reflected a net
loss of $77,142 for October.

As of October 31, 2023, EPI Health listed $22.75 million in total
assets, $25.86 million in total liabilities, and -$3.1 million in
total shareholders' equity

EPI Health started the month with $4.81 million cash. It listed
total cash receipts of $595,025 and total disbursements of $2.6
million. At month end, EPI Health had $5.26 million cash.

Copies of the monthly operating reports are available at the SEC
at:

                https://tinyurl.com/2p82f8kz
                https://tinyurl.com/3rdr4bsw

                       About Novan, Inc.

Based in Durham, N.C., Novan, Inc., (Nasdaq: NOVN), now known as
NVN Liquidation, Inc., is a clinical development-stage
biotechnology company focused on leveraging nitric oxide's
naturally occurring anti-viral, anti-bacterial, anti-fungal and
immunomodulatory mechanisms of action to treat a range of diseases
with significant unmet needs. Nitric oxide plays a vital role in
the natural immune system response against microbial pathogens and
is a critical regulator of inflammation.

Novan Inc. and affiliate, EPI Health, LLC, filed Chapter 11
petitions (Bankr. D. Del. Lead Case No. 23-10937) on July 17, 2023.
As of March 31, 2023, Novan disclosed $79,793,000 in assets
against $7,922,000 in liabilities.

Judge Laurie Selber Silverstein oversees the cases.

The Debtors tapped Morris, Nichols, Arsht & Tunnell, LLP as
bankruptcy counsel; Smith, Anderson, Blount, Dorsett, Mitchell &
Jernigan, LLP as special counsel; Sierra Constellation Partners,
LLC as financial advisor; and Raymond James and Associates as
investment banker. Kurtzman Carson Consultants, LLC is the claims
agent.

On July 28, 2023, the U.S. Trustee for Regions 3 and 9 appointed an
official committee of unsecured creditors in these Chapter 11
cases. The committee tapped Goodwin Procter, LLP as bankruptcy
counsel; Womble Bond Dickinson (US) LLP as co-counsel; and Dundon
Advisers, LLC as financial advisor.

On October 16, 2023, the Bankruptcy Court approved the change of
Novan Inc.'s corporate name to NVN Liquidation Inc.


                            *********

Monday's edition of the TCR delivers a list of indicative prices
for bond issues that reportedly trade well below par.  Prices are
obtained by TCR editors from a variety of outside sources during
the prior week we think are reliable.  Those sources may not,
however, be complete or accurate.  The Monday Bond Pricing table
is compiled on the Friday prior to publication.  Prices reported
are not intended to reflect actual trades.  Prices for actual
trades are probably different.  Our objective is to share
information, not make markets in publicly traded securities.
Nothing in the TCR constitutes an offer or solicitation to buy or
sell any security of any kind.  It is likely that some entity
affiliated with a TCR editor holds some position in the issuers
public debt and equity securities about which we report.

Each Tuesday edition of the TCR contains a list of companies with
insolvent balance sheets whose shares trade higher than $3 per
share in public markets.  At first glance, this list may look like
the definitive compilation of stocks that are ideal to sell short.
Don't be fooled.  Assets, for example, reported at historical cost
net of depreciation may understate the true value of a firm's
assets.  A company may establish reserves on its balance sheet for
liabilities that may never materialize.  The prices at which
equity securities trade in public market are determined by more
than a balance sheet solvency test.

On Thursdays, the TCR delivers a list of recently filed
Chapter 11 cases involving less than $1,000,000 in assets and
liabilities delivered to nation's bankruptcy courts.  The list
includes links to freely downloadable images of these small-dollar
petitions in Acrobat PDF format.

Each Friday's edition of the TCR includes a review about a book of
interest to troubled company professionals.  All titles are
available at your local bookstore or through Amazon.com.  Go to
http://www.bankrupt.com/books/to order any title today.

Monthly Operating Reports are summarized in every Saturday edition
of the TCR.

The Sunday TCR delivers securitization rating news from the week
then-ending.

TCR subscribers have free access to our on-line news archive.
Point your Web browser to http://TCRresources.bankrupt.com/and use
the e-mail address to which your TCR is delivered to login.

                            *********

S U B S C R I P T I O N   I N F O R M A T I O N

Troubled Company Reporter is a daily newsletter co-published
by Bankruptcy Creditors Service, Inc., Fairless Hills,
Pennsylvania, USA, and Beard Group, Inc., Philadelphia, Pa., USA.
Randy Antoni, Jhonas Dampog, Marites Claro, Joy Agravante,
Rousel Elaine Tumanda, Joel Anthony G. Lopez, Psyche A. Castillon,
Ivy B. Magdadaro, Carlo Fernandez, Christopher G. Patalinghug, and
Peter A. Chapman, Editors.

Copyright 2023.  All rights reserved.  ISSN: 1520-9474.

This material is copyrighted and any commercial use, resale or
publication in any form (including e-mail forwarding, electronic
re-mailing and photocopying) is strictly prohibited without prior
written permission of the publishers.  Information contained
herein is obtained from sources believed to be reliable, but is
not guaranteed.

The TCR subscription rate is $975 for 6 months delivered via
e-mail.  Additional e-mail subscriptions for members of the same
firm for the term of the initial subscription or balance thereof
are $25 each.  For subscription information, contact Peter A.
Chapman at 215-945-7000.

                   *** End of Transmission ***